Literature DB >> 10892894

Biotransformation of deprenyl enantiomers.

E Szökö1, H Kalász, K Magyar.   

Abstract

Rats were treated with either (-)- or (+)-deprenyl, and the metabolites extracted from the plasma, liver, kidney and heart homogenates were studied by chiral capillary electrophoresis (CE). Stereoselective dealkylation of both optical isomers with the formation of desmethyldeprenyl (DD), methamphetamine (MA), and amphetamine (A) was found. (-)-MA appears to be the main metabolite of (-)-D, and (+)-A for (+)-D. This suggests that the enantiomers undergo a different dealkylation process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10892894     DOI: 10.1007/BF03190039

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  11 in total

1.  Chromatographic studies on the binding, action and metabolism of (-)-deprenyl.

Authors:  H Kalász; L Kerecsen; J Knoll; J Pucsok
Journal:  J Chromatogr       Date:  1990-01-19

2.  Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.

Authors:  T Yoshida; Y Yamada; T Yamamoto; Y Kuroiwa
Journal:  Xenobiotica       Date:  1986-02       Impact factor: 1.908

3.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250).

Authors:  K Magyar; E S Vizi; Z Ecseri; J Knoll
Journal:  Acta Physiol Acad Sci Hung       Date:  1967

5.  Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences.

Authors:  T Yoshida; T Oguro; Y Kuroiwa
Journal:  Xenobiotica       Date:  1987-08       Impact factor: 1.908

6.  Postmortem tissue methamphetamine concentrations following selegiline administration.

Authors:  J E Meeker; P C Reynolds
Journal:  J Anal Toxicol       Date:  1990 Sep-Oct       Impact factor: 3.367

7.  Urinary excretion of deprenyl metabolites.

Authors:  J Lengyel; K Magyar; I Hollósi; T Bartók; M Báthori; H Kalász; S Fürst
Journal:  J Chromatogr A       Date:  1997-02-21       Impact factor: 4.759

Review 8.  Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.

Authors:  E H Heinonen; M I Anttila; R A Lammintausta
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

9.  The distribution of orally administered (-)-deprenyl-propynyl-14C and (-)-deprenyl-phenyl-3H in rat brain.

Authors:  K Magyar; J Lengyel; I Szatmári; J Gaál
Journal:  Prog Brain Res       Date:  1995       Impact factor: 2.453

10.  Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma.

Authors:  G Szebeni; J Lengyel; G Székács; K Magyar; J Gaál; I Szatmári
Journal:  Acta Physiol Hung       Date:  1995
View more
  4 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

3.  Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

Authors:  Zaid A Abassi; Ofer Binah; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

Review 4.  Selegiline: a molecule with innovative potential.

Authors:  Tamás Tábi; László Vécsei; Moussa B Youdim; Peter Riederer; Éva Szökő
Journal:  J Neural Transm (Vienna)       Date:  2019-09-27       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.